ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces the appointment of Northland Capital Partners as joint broker to the Company, alongside Panmure Gordon with immediate effect.

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor™, the Company’s lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial. This event, to…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that the first European sites opened…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 30 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming that it has increased its holding to 5,053,548 million Ordinary Shares in the capital of the Company. This represents 4.15% of ImmuPharma’s total voting…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that on 24 May 2016 it received notification by Alto Invest and its subsidiaries (“Alto”) confirming its holding in ImmuPharma of 4,870,367 million Ordinary Shares in the capital of the Company, representing 3.99% of the Company’s total voting rights, crossing…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary  results for the year ended 31 December 2015. Key Highlights: Lupuzor™ Pivotal Phase III clinical trial for Lupuzor™, the Company’s lead programme for the potential breakthrough compound for Lupus, is progressing, in conjunction with Simbec-Orion,…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2015 has been posted to shareholders. The 2015 Annual Report can be downloaded here The Company’s Annual General Meeting will be held on Thursday 26 May 2016 at…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that it will announce its Preliminary results for the year ended 31 December 2015 on Wednesday 4 May 2016. For further information on meetings scheduled around the Preliminary results roadshow or media enquiries, please contact Lisa Baderoon on lisa.baderoon@immupharm.com

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. ImmuPharma is pleased to confirm that…

ImmuPharma PLC (LSE:IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from HM Revenue and Customs that it is a qualifying holding for the purposes of the Venture Capital Trust rules (“VCT Advance Assurance”) and a qualifying company for the purposes of the Enterprise Investment…